Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
17 studies found for:    Open Studies | Exclude Unknown | pancreatic disease | NIDDK
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Studying Patients With Cystic Fibrosis and Other Pulmonary and Pancreatic Disorders
Condition: Cystic Fibrosis
Intervention:
2 Recruiting Blood Flow and Vascular Function in Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Drug: Acute (1 hour) Sildenafil;   Drug: Sub-Chronic (4 weeks) Sildenafil;   Drug: Placebo
3 Recruiting Natural History of Noncirrhotic Portal Hypertension
Conditions: Cystic Fibrosis;   Immunologic Deficiency Syndrome;   Turner Syndrome;   Congenital Hepatic Fibrosis;   Idiopathic Non-Cirrhotic Portal Hypertension
Intervention:
4 Recruiting Diagnosing and Treating Low Blood Sugar Levels
Conditions: Hypoglycemia;   Insulinoma
Intervention:
5 Recruiting Fat Malabsorption in Chronic Pancreatitis
Condition: Chronic Pancreatitis
Intervention: Drug: Creon36™
6 Recruiting UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource
Conditions: Hepato/Renal Fibrocystic Disease;   Autosomal Recessive Polycystic Kidney Disease;   Joubert Syndrome;   Bardet Biedl Syndrome;   Meckel-Gruber Syndrome;   Congenital Hepatic Fibrosis;   Caroli Syndrome;   Oro-Facial-Digital Syndrome Type I;   Nephronophthisis;   Glomerulocystic Kidney Disease
Intervention:
7 Recruiting Genetic Modifiers of Cystic Fibrosis Related Diabetes
Condition: Cystic Fibrosis Related Diabetes
Intervention:
8 Recruiting Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance
Condition: Cystic Fibrosis
Intervention:
9 Recruiting BioEnergetics and Metabolomics in Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention:
10 Recruiting Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
Condition: Post-ERCP Pancreatitis
Interventions: Other: Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement;   Other: Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
11 Recruiting Mesenchymal Stem Cell and Islet Co-transplantation
Conditions: Chronic Pancreatitis;   Diabetes
Intervention: Biological: autologous mesenchymal stromal cell
12 Recruiting MMPPC: A Probabilistic Closed-loop Artificial Pancreas to Handle Unannounced Meals and Exercise
Condition: Type 1 Diabetes
Interventions: Device: Inpatient use of the MMPPC/DiAs system;   Device: Outpatient use of the MMPPC/DiAs system
13 Not yet recruiting Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents
Conditions: Type 1 Diabetes;   Hypoglycemia;   Hyperglycemia;   Artificial Pancreas
Intervention: Device: Hyperglycemia Minimization Algorithm
14 Not yet recruiting International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol
Condition: Diabetes Mellitus, Type 1
Intervention: Device: Artificial Pancreas
15 Recruiting Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control
Condition: Diabetes Mellitus, Type 1
Intervention: Device: CLC
16 Recruiting USS Virginia Closed-Loop Versus SAP Therapy for Hypoglycemia Reduction in T1D
Condition: Type 1 Diabetes Mellitus
Interventions: Device: DiAs with USS Virginia;   Device: Sensor-Augmented Pump Therapy (placebo)
17 Recruiting Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
Condition: Type 1 Diabetes Mellitus
Intervention: Device: Decision Support System

Indicates status has not been verified in more than two years